Skip to main content

entrectinib

Generic: ENTRECTINIB·Brand: ROZLYTREK, Rozlytrek

entrectinib: 7 clinical trials tracked.

entrectinib evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about entrectinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 4 study sponsors
Clinical Trials (7)

PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)

NCT06528691·Phase 2·FLNA
Recruiting

Primary endpoint: Overall response rate (ORR) (Cohort 1)

Interventionalopen52 targetStarted 2026-03Completion 2032-112 sites · Jordan, United StatesSt. Jude Children's Research Hospital

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

NCT05862285·Phase 3·ENTA
Recruiting

Primary endpoint: Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)

Interventionalopen100 targetStarted 2023-06Completion 2033-0350 sites · Belgium, Canada, China, Costa Rica…Hoffmann-La Roche

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations

NCT05722886·Phase 2/Phase 3
Recruiting

Primary endpoint: Number of patients who consent to each arm.

Interventionalopen825 targetStarted 2023-03Completion 2029-1027 sites · United KingdomCancer Research UK

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

NCT04589845·Phase 2·ENTA
Recruiting

Primary endpoint: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Interventionalopen920 targetStarted 2021-01Completion 2032-0950 sites · United StatesHoffmann-La Roche

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

NCT04302025·Phase 2·MRUS
Recruiting

Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)

Interventionalopen99 targetStarted 2020-11Completion 2030-0538 sites · United StatesGenentech, Inc.

Genomically-Guided Treatment Trial in Brain Metastases

NCT03994796·Phase 2·CGON
Active, not recruiting

Primary endpoint: Objective response rate in the brain

Interventionalopen50 targetStarted 2019-10Completion 2028-0650 sites · United StatesAlliance for Clinical Trials in Oncology

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute